The CD40/CD40L system: A new therapeutic target for disease

Immunology Letters

Volumn 153, Issue 1-2, 2013, Pages 58-61

  Zhang, Bikui ^a   Wu, Tian ^a   Chen, Min ^a   Zhou, Yulu ^a   Yi, Dongyang ^a   Guo, Ren ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CD40 CD40L; Clopidogrel; Monoclonal antibodies (mAbs); SGN 40; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ANTIBODY; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CD40 ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CLOPIDOGREL; DACETUZUMAB; FIBRINOGEN RECEPTOR ANTAGONIST; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY 4D11; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN CFM40L; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; BLADDER CARCINOMA; CANCER INHIBITION; CEREBROVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; KIDNEY ALLOGRAFT; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

CD40/CD40L; CLOPIDOGREL; MONOCLONAL ANTIBODIES (MABS); SGN-40; STATINS;

ANTIGENS, CD40; ATHEROSCLEROSIS; CD40 LIGAND; CYTOKINES; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84882797420     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.07.005     Document Type: Review

References (52)

1. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., Cavusoglu E., Marmur J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thrombosis and Haemostasis 2003, 90:377-384.
2. Chakrabarti S., Rizvi M., Pathak D., Kirber M.T., Freedman J.E. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunology Letters 2009, 122:170-184.
3. Jeon H.J., Choi J.H., Jung I.H., Park J.G., Lee M.R., Lee M.N., et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010, 121:1124-1133.
4. Nomura S., Shouzu A., Omoto S., Inami N., Shimazu T., Satoh D., et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagulation and Fibrinolysis 2009, 20:440-447.
5. Aggarwal A., Blum A., Schneider D.J., Sobel B.E., Dauerman H.L. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coronary Artery Disease 2004, 15:471-475.
6. Cipollone F., Chiarelli F., Davi G., Ferri C., Desideri G., Fazia M., et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005, 48:1216-1224.
7. Ueland T., Aukrust P., Yndestad A., Otterdal K., Froland S.S., Dickstein K., et al. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal 2005, 26:1101-1107.
8. Oviedo-Orta E., Bermudez-Fajardo A., Karanam S., Benbow U., Newby A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008, 124:42-50.
9. Hollenbaugh D., Mischel-Petty N., Edwards C.P., Simon J.C., Denfeld R.W., Kiener P.A., et al. Expression of functional CD40 by vascular endothelial cells. The Journal of Experimental Medicine 1995, 182:33-40.
10. Hernandez M.G., Shen L., Rock K.L. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. The Journal of Immunology 2007, 178:2844-2852.
11. Callard R.E., Armitage R.J., Fanslow W.C., Spriggs M.K. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunology Today 1993, 14:559-564.
12. Lopez-Granados E., Temmerman S.T., Wu L., Reynolds J.C., Follmann D., Liu S., et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:5056-5061.
13. Ochs H.D., Hollenbaugh D., Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Seminars in Immunology 1994, 6:337-341.
14. Li R., Chen W.C., Pang X.Q., Tian W.Y., Wang W.P., Zhang X.G., et al. CD40 signal expression in gastric cancer tissue and its correlation with prognosis of gastric cancer patients. Molecular Biology Reports 2012.
15. Li R., Chen W.C., Wang W.P., Tian W.Y., Zhang X.G. CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells. Immunology Letters 2010, 131:120-125.
16. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999, 100:614-620.
17. Chen Y., Chen J., Xiong Y., Da Q., Xu Y., Jiang X., et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochemical and Biophysical Research Communications 2006, 345:106-117.
18. Rondina M.T., Lappe J.M., Carlquist J.F., Muhlestein J.B., Kolek M.J., Horne B.D., et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 2008, 109:196-201.
19. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003, 108:1049-1052.
20. Mach F., Schonbeck U., Sukhova G.K., Atkins E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
21. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6930-6932.
22. Li J., Zhao S.P., Peng D.Q., Xu Z.M., Zhou H.N. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clinical Chemistry 2004, 50:1696-1699.
23. Semb A.G., van W.S., Ueland T., Smilde T., Waehre T., Tripp M.D., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. Journal of the American College of Cardiology 2003, 41:275-279.
24. Santini E., Madec S., Corretti V., Ferrannini E., Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. Journal of Endocrinological Investigation 2008, 31:660-665.
25. Kinlay S., Schwartz G.G., Olsson A.G., Rifai N., Sasiela W.J., Szarek M., et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004, 110:386-391.
26. Lee Y., Lee W.H., Lee S.C., Ahn K.J., Choi Y.H., Park S.W., et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999, 92:11-16.
27. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997, 96:396-399.
28. Urbich C., Mallat Z., Tedgui A., Clauss M., Zeiher A.M., Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. Journal of Clinical Investigation 2001, 108:1451-1458.
29. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. The New England Journal of Medicine 2003, 348:1104-1111.
30. Yip H.K., Chang L.T., Sun C.K., Yang C.H., Hung W.C., Cheng C.I., et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. American Journal of Cardiology 2006, 97:192-194.
31. Saw J., Madsen E.H., Chan S., Maurer-Spurej E. The ELAPSE evaluation of long-term clopidogrel antiplatelet and systemic anti-inflammatory effects study. Journal of the American College of Cardiology 2008, 52:1826-1833.
32. Chandler A.B., Earhart A.D., Speich H.E., Kueter T.J., Hansen J., White M.M., et al. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Thrombosis Research 2010, 125:44-52.
33. Eliopoulos A.G., Young L.S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Current Opinion in Pharmacology 2004, 4:360-367.
34. Elmetwali T., Young L.S., Palmer D.H. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. Journal of Immunology 2010, 184:1111-1120.
35. Pedersen I.M., Kitada S., Leoni L.M., Zapata J.M., Karras J.G., Tsukada N., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
36. Vonderheide R.H., Agonistic Glennie M.J. CD40 antibodies and cancer therapy. Clinical Cancer Research 2013, 19:1035-1043.
37. Tutt A.L., O'Brien L., Hussain A., Crowther G.R., French R.R., Glennie M.J. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. Journal of Immunology 2002, 168:2720-2728.
38. Hamzah J., Nelson D., Moldenhauer G., Arnold B., Hammerling G.J., Ganss R. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. Journal of Clinical Investigation 2008, 118:1691-1699.
39. Qi C.J., Qian K.Q., Ning Y.L., Ma H.B., Wang S.Z., Zhang X.G. Ligation or cross-linking of CD40 has different effects on AGS gastric cancer cells. Cellular Immunology 2009, 259:135-140.
40. Li R., Chen W.C., Pang X.Q., Tian W.Y., Zhang X.G. Influence of sCD40L on gastric cancer cell lines. Molecular Biology Reports 2011, 38:5459-5464.
41. Kim Y.S., Kim Y.J., Lee J.M., Han S.H., Ko H.J., Park H.J., et al. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Human Gene Therapy 2010, 21:1697-1706.
42. Li R., Chen W.C., Pang X.Q., Hua C., Li L., Zhang X.G. Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. International Journal of Molecular Sciences 2009, 10:3900-3917.
43. Xu W., Li Y., Wang X., Wang C., Zhao W., Wu J., et al. Anti-tumor activity of gene transfer of the membrane-stable CD40L mutant into lung cancer cells. International Journal of Oncology 2010, 37:935-941.
44. Liu S., Chen B., Li Y., Zhao W., Wu J. Effect of sCD40L combined with vinorelbine on lung adenocarcinoma cell A549. Zhongguo Fei Ai Za Zhi 2010, 13:686-690.
45. Wang Z., Morelli A.E., Hackstein H., Kaneko K., Thomson A.W. Marked inhibition of transplant vascular sclerosis by in vivo-mobilized donor dendritic cells and anti-CD154 mAb. Transplantation 2003, 76:562-571.
46. Tung T.H., Mackinnon S.E., Mohanakumar T. Costimulation blockade of CD40 and CD28 pathways in limb transplantation. Transplantation Proceedings 2008, 40:3723-3724.
47. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine 2000, 6:114.
48. Koyama I., Kawai T., Andrews D., Boskovic S., Nadazdin O., Wee S.L., et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004, 77:460-462.
49. Ankersmit H.J., Roth G.A., Moser B., Zuckermann A., Brunner M., Rosin C., et al. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. American Journal of Transplantation 2003, 3:754-759.
50. Aoyagi T., Yamashita K., Suzuki T., Uno M., Goto R., Taniguchi M., et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. American Journal of Transplantation 2009, 9:1732-1741.
51. Lievens D., Eijgelaar W.J., Biessen E.A., Daemen M.J., Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thrombosis and Haemostasis 2009, 102:206-214.
52. Nakamura M., Tanaka Y., Satoh T., Kawai M., Hirakata M., Kaburaki J., et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford) 2006, 45:150-156.